TABLE 4.

HIV-1 sequence mutations at positions which are also known drug resistance mutations and numbers of patients exhibiting the indicated HLA type who received the indicated drug type

Drug or resistance type	Polymorphisma	HLA typeb	No. of patients with HIV-1 sequence mutation:		No. of patients (%) who received drugs	Newd
			Absentc	Present
Tipranavir-ritonavir	PRO-E35x	HLA-B*44	11	24	0 of 24 (0)	Y
		Non-HLA-B*44	120	24	0 of 155 (0)
	PRO-E35x	HLA-A*68	11	13	0 of 35 (0)	Y
		Non-HLA-A*68	120	35	0 of 144 (0)
Many currently used PIs	PRO-I54x	HLA-B*57	5	6	10 of 11 (90.9)	Y
		Non-HLA-B*57	145	23	117 of 168 (69.6)
	PRO-V82x	HLA-B*57	5	6	10 of 11 (90.9)	Y
		Non-HLA-B*57	142	26	117 of 168 (69.6)
Atazanavir	PRO-Q92x	HLA-B*15	22	8	0 of 30 (0)	Y
		Non-HLA-B*15	146	3	0 of 149 (0)
Multi-NRTI resistance	RT-D67x	HLA-DRB1*08	1	6	7 of 7 (100)	Y
		Non-HLA-DRB1*08	120	52	158 of 172 (91.8)
	RT-V75x	HLA-B*57	6	5	11 of 11 (100)	Y
		Non-HLA-B*57	154	14	154 of 168 (91.6)
NNRTIs	RT-Y188x	HLA-DRB1*12	5	3	5 of 8 (62.5)	Y
		Non-HLA-DRB1*12	167	4	84 of 171 (49.1)

^aHIV-1 sequence mutation in the protease or RT.

^bSpecific HLA type for which the mutation was found.

^cPatients without the indicated HIV-1 sequence mutation had the corresponding wild-type amino acid.

^dY indicates that the association is new; N indicates that it has already been described in the literature.